Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agilon Health (AGL) EBIT (2020 - 2025)

Agilon Health's EBIT history spans 6 years, with the latest figure at -$193.8 million for Q4 2025.

  • For Q4 2025, EBIT fell 79.3% year-over-year to -$193.8 million; the TTM value through Dec 2025 reached -$463.2 million, down 58.57%, while the annual FY2025 figure was -$463.2 million, 58.57% down from the prior year.
  • EBIT reached -$193.8 million in Q4 2025 per AGL's latest filing, down from -$131.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $417000.0 in Q1 2023 to a low of -$298.4 million in Q2 2021.
  • Average EBIT over 5 years is -$73.3 million, with a median of -$37.4 million recorded in 2021.
  • Peak YoY movement for EBIT: crashed 23730.91% in 2021, then soared 156.12% in 2023.
  • A 5-year view of EBIT shows it stood at -$26.2 million in 2021, then tumbled by 106.65% to -$54.1 million in 2022, then plummeted by 203.89% to -$164.3 million in 2023, then skyrocketed by 34.21% to -$108.1 million in 2024, then tumbled by 79.3% to -$193.8 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's EBIT are -$193.8 million (Q4 2025), -$131.3 million (Q3 2025), and -$116.0 million (Q2 2025).